Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.

SGLT2 inhibitor provides greater weight loss benefits than metformin, gliptins

17 Feb 2019

In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.

Researchers searched multiple online databases for relevant randomized controlled trials evaluating the effect of different SGLT2 inhibitors vs other glucose-lowering medications on weight in T2D patients. The studies had to be 12 weeks in length and assess change in weight from baseline, ideally reporting the proportion of patients achieving a 5-percent weight reduction.

The meta-analysis included 29 randomized controlled trials with a low risk of bias, involving 11,999 patients. Researchers used the DerSimonian-Laird and Bayesian Markov chain Monte Carlo random effects models.

Pooled data revealed that SGLT2 monotherapy led to a mean weight loss ranging from −2.26 kg (95 percent credible interval, −2.71 to −1.76) with canagliflozin 300 mg to −0.79 kg (−1.54 to −0.05) with ipragliflozin 25 mg when compared with metformin.

Relative to linagliptin and sitagliptin, the mean weight loss ranged from −3.17 kg (−3.67 to −2.57) with canagliflozin 300 mg to −0.93 kg (−1.92 to 0.05) with ipragliflozin 25 mg.

Among other SGLT2 inhibitors, canagliflozin 300 mg yielded the greatest effect on weight with a probability of 99.44 percent.

SGLT2 inhibitors also increased the number of patients achieving ≥5-percent weight loss, with their effect on weight reduction correlated with treatment dosage.

Currently, the mechanism through which SGLT inhibitors affect weight is a topic of great interest. Evidence suggests that selective SGLT2 inhibitors mainly exert their effects on weight loss by lowering the reabsorption of glucose, leading to an increase in urinary glucose excretion. [Clin Ther 2015;37:1150-1166]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.